Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluticasone Propionate/Salmeterol vs Fluticasone Propionate in Pediatric Activity-Induced Bronchospasm
NCT00118716Phase 4Completed
- Sponsor
- GSK
- Start
- Dec 2003
- Primary completion
- Apr 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of salmeterol in asthma and exercise-induced bronchospasm (EIB) (2 arms), sponsored by GSK. Primary endpoint: Maximal Percent Change in Forced Expiratory Volume in 1 Second (FEV1) Following Exercise Challenge at Week 4. Started Dec 2003; status: completed.
02
Drugs
salmeterol
03
Conditions
asthmaexercise-induced bronchospasm (EIB)
Beyond the preview
Go deeper on NCT00118716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00118716.